358 related articles for article (PubMed ID: 28143691)
1. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies.
Katial RK; Bensch GW; Busse WW; Chipps BE; Denson JL; Gerber AN; Jacobs JS; Kraft M; Martin RJ; Nair P; Wechsler ME
J Allergy Clin Immunol Pract; 2017; 5(2S):S1-S14. PubMed ID: 28143691
[TBL] [Abstract][Full Text] [Related]
2. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
3. Prospects for Monoclonal Antibody Therapy in Pediatric Asthma.
Generoso A; Muglia-Chopra C; Oppenheimer J
Curr Allergy Asthma Rep; 2018 Jul; 18(9):45. PubMed ID: 29992472
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
5. Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5.
Chambliss JM; Sur S; Tripple JW
Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):26-31. PubMed ID: 29257776
[TBL] [Abstract][Full Text] [Related]
6. Future biologic therapies in asthma.
Quirce S; Bobolea I; Domínguez-Ortega J; Barranco P
Arch Bronconeumol; 2014 Aug; 50(8):355-61. PubMed ID: 24685200
[TBL] [Abstract][Full Text] [Related]
7. Biologics in the treatment of severe asthma.
Quirce S; Phillips-Angles E; Domínguez-Ortega J; Barranco P
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():45-49. PubMed ID: 29108767
[TBL] [Abstract][Full Text] [Related]
8. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
Mavissakalian M; Brady S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
[TBL] [Abstract][Full Text] [Related]
9. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
10. Biologic Therapy and Novel Molecular Targets of Severe Asthma.
Pepper AN; Renz H; Casale TB; Garn H
J Allergy Clin Immunol Pract; 2017; 5(4):909-916. PubMed ID: 28689841
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory and biologic therapies for severe refractory asthma.
Polosa R; Morjaria J
Respir Med; 2008 Nov; 102(11):1499-510. PubMed ID: 19012848
[TBL] [Abstract][Full Text] [Related]
12. Patient Characteristics and Individualization of Biologic Therapy.
Draikiwicz S; Oppenheimer J
Immunol Allergy Clin North Am; 2017 May; 37(2):261-281. PubMed ID: 28366476
[TBL] [Abstract][Full Text] [Related]
13. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
Fajt ML; Wenzel SE
J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
15. Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.
Silkoff PE; Strambu I; Laviolette M; Singh D; FitzGerald JM; Lam S; Kelsen S; Eich A; Ludwig-Sengpiel A; Hupp GC; Backer V; Porsbjerg C; Girodet PO; Berger P; Leigh R; Kline JN; Dransfield M; Calhoun W; Hussaini A; Khatri S; Chanez P; Susulic VS; Barnathan ES; Curran M; Das AM; Brodmerkel C; Baribaud F; Loza MJ
Respir Res; 2015 Nov; 16():142. PubMed ID: 26576744
[TBL] [Abstract][Full Text] [Related]
16. A pathophysiological approach for FeNO: A biomarker for asthma.
Ricciardolo FL; Sorbello V; Ciprandi G
Allergol Immunopathol (Madr); 2015; 43(6):609-16. PubMed ID: 25796309
[TBL] [Abstract][Full Text] [Related]
17. Recent changes in the drug treatment of allergic asthma.
Gibeon D; Menzies-Gow A
Clin Med (Lond); 2013 Oct; 13(5):477-81. PubMed ID: 24115705
[TBL] [Abstract][Full Text] [Related]
18. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
Upham JW; Jurak LM
Clin Exp Allergy; 2020 Sep; 50(9):994-1006. PubMed ID: 32569412
[TBL] [Abstract][Full Text] [Related]
19. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in Severe Asthma.
Wan XC; Woodruff PG
Immunol Allergy Clin North Am; 2016 Aug; 36(3):547-57. PubMed ID: 27401625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
